In first line, iadademstat with azacitidine and venetoclax continues to show favorable safety and 100% ORR, with a composite complete remission rate (CRc) of 93% (with 79% CR), and an estimated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results